I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| endothelial cell | 19 studies | 28% ± 8% | |
| ciliated cell | 13 studies | 29% ± 9% | |
| oligodendrocyte | 12 studies | 25% ± 10% | |
| oligodendrocyte precursor cell | 11 studies | 27% ± 12% | |
| natural killer cell | 11 studies | 17% ± 2% | |
| glutamatergic neuron | 10 studies | 42% ± 25% | |
| astrocyte | 10 studies | 32% ± 13% | |
| type I pneumocyte | 9 studies | 29% ± 10% | |
| microglial cell | 9 studies | 27% ± 9% | |
| macrophage | 7 studies | 28% ± 6% | |
| fibroblast | 7 studies | 19% ± 3% | |
| GABAergic neuron | 7 studies | 43% ± 21% | |
| interneuron | 6 studies | 38% ± 23% | |
| epithelial cell | 6 studies | 36% ± 16% | |
| retinal cone cell | 6 studies | 34% ± 9% | |
| retinal rod cell | 6 studies | 41% ± 10% | |
| endothelial cell of lymphatic vessel | 6 studies | 27% ± 5% | |
| type II pneumocyte | 6 studies | 22% ± 6% | |
| neuron | 5 studies | 36% ± 12% | |
| myeloid cell | 5 studies | 22% ± 5% | |
| dendritic cell | 5 studies | 27% ± 15% | |
| CD16-positive, CD56-dim natural killer cell, human | 4 studies | 17% ± 2% | |
| retina horizontal cell | 4 studies | 19% ± 3% | |
| cardiac muscle cell | 4 studies | 24% ± 5% | |
| Mueller cell | 4 studies | 18% ± 2% | |
| gamma-delta T cell | 4 studies | 22% ± 11% | |
| CD4-positive, alpha-beta T cell | 3 studies | 19% ± 2% | |
| non-classical monocyte | 3 studies | 23% ± 10% | |
| GABAergic interneuron | 3 studies | 22% ± 6% | |
| retinal ganglion cell | 3 studies | 29% ± 6% | |
| adipocyte | 3 studies | 17% ± 2% | |
| lymphocyte | 3 studies | 20% ± 3% | |
| CD8-positive, alpha-beta T cell | 3 studies | 19% ± 2% | |
| regulatory T cell | 3 studies | 17% ± 1% | |
| muscle cell | 3 studies | 23% ± 5% | |
| B cell | 3 studies | 18% ± 2% | |
| myofibroblast cell | 3 studies | 19% ± 3% | |
| T cell | 3 studies | 20% ± 6% | |
| alveolar macrophage | 3 studies | 25% ± 7% | |
| monocyte | 3 studies | 24% ± 4% | |
| pericyte | 3 studies | 17% ± 2% | |
| basal cell | 3 studies | 34% ± 7% | |
| transit amplifying cell | 3 studies | 30% ± 18% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 17% ± 1% | |
| erythroblast | 3 studies | 25% ± 13% |
